Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Antidepressant

or Dissociative

or Opioid

Use the filters below to narrow your results.

Codeine (2)

None (30)

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Irreversible non-selective MAO inhibitor (3) · NMDA antagonist (3) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · NMDA antagonist; sigma receptor agonist (2) · Serotonin–norepinephrine reuptake inhibitor (2)

Other values:

None (67) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Mild to moderate pain; cough suppression (low-dose). (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (67) · 25 mg (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (67) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 28 mg/device (each dose uses 2 devices) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (67) · 200 mg/d (1) · 360 mg/day (1) · 84 mg per session (1)

None (66) · Intranasal (under direct medical supervision) (1) · Oral (2) · PO (only formulation marketed in the US). (1)

None (66) · 30–60 min (PO) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Within hours of first administration (1)

None (66) · 4–6 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Chronic daily dosing (1) · Long (1)

None (66) · 2.5–3 hours (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~7-12 hours (1)

None (66) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~48% intranasal (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (66) · Avoid; may cause fetal harm (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)

None (66) · Rx, Schedule III (US). REMS program required. (1) · Rx-only (1) · Rx-only in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 71 results in range #1 to #71.

2

2-FDCK

3

4

4-MeO-PCP

7

7-Hydroxymitragynine

A

B

C

D

E

F

Fentanyl

H

I

K

Kratom

L

M

N

Nitrous oxide

O

P

R

S

T

U

U-47700

X

Xenon

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"